OCULAR THERAPEUTIX, INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Ocular Therapeutix (OCUL) completed a Pre-NDA meeting with the FDA for AXPAXLI, its wet AMD treatment. The meeting confirmed the NDA submission plan for Q4 2026, supported by Phase 3 trial data. AXPAXLI is also in trials for diabetic retinal disease. OCUL stock is up 2.19% to $10.72.
Ocular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.
Ocular Therapeutix (OCUL) has a notice of proposed sale of 1,099 shares of common stock by Donald D. Notman Jr. The shares, valued at $11,251.89, are restricted stock vesting under a registered plan and will be sold through Morgan Stanley Smith Barney LLC. The transaction is set for August 31, 2026, with the stock vesting on August 29, 2026.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning OCUL (OCULAR THERAPEUTIX, INC). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OCUL coverage spans market movers, financial news and earnings.
In the last 30 days, OCUL insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($333K). The most active reporter was Notman Donald, Chief Operating Officer, with 1 filing. 80% of those filings were made under pre-arranged Rule 10b5-1 plans.
Regulatory clearance path confirmed, likely boosting near-term stock momentum.
Potential upside if NDA filing proceeds on schedule and trial data supports reduced injection frequency.
Minor dilution from insider sale; unlikely to move price materially.
Ocular Therapeutix's Executive Chairman, Pravin Dugel, sold $233k worth of shares at $10.77 each, following a larger sale earlier this year. Insiders have sold more shares than they bought in the past year, with total insider ownership at 1.2% of the company. The insider activity does not strongly indicate confidence in the stock's value.
The insider sell may signal short‑term selling pressure but is a routine tax‑related transaction.
AlphAI scores every news story that mentions OCUL with an AI model for sentiment and relevance, and aggregates insider trades from OCULAR THERAPEUTIX, INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ocular Therapeutix (OCUL) completed a Pre-NDA meeting with the FDA for AXPAXLI, its wet AMD treatment. The meeting confirmed the NDA submission plan for Q4 2026, supported by Phase 3 trial data. AXPAXLI is also in trials for diabetic retinal disease. OCUL stock is up 2.19% to $10.72.
2 min readOcular Therapeutix (OCUL) reported Q2 2026 results, highlighting AXPAXLI's progress for wet age-related macular degeneration. The FDA confirmed the NDA filing timeline, with potential for a faster review. Costs rose, with R&D at $54.1M, marketing at $17.3M, and net loss widening to $78.8M. Cash reserves decreased to $598.6M. AXPAXLI's data suggests fewer patient injections, and early market research shows high adoption potential. Institutional interest grew, but short interest remains high.
3 min readOcular Therapeutix (OCUL) has a notice of proposed sale of 1,099 shares of common stock by Donald D. Notman Jr. The shares, valued at $11,251.89, are restricted stock vesting under a registered plan and will be sold through Morgan Stanley Smith Barney LLC. The transaction is set for August 31, 2026, with the stock vesting on August 29, 2026.
1 min readOcular Therapeutix's Executive Chairman, Pravin Dugel, sold $233k worth of shares at $10.77 each, following a larger sale earlier this year. Insiders have sold more shares than they bought in the past year, with total insider ownership at 1.2% of the company. The insider activity does not strongly indicate confidence in the stock's value.
2 min readOcular Therapeutix (OCUL) CEO Pravin Dugel sold 21,649 shares at $10.77 each to cover tax obligations, retaining 2,525,429 shares. His spouse transferred 50,092 shares to a trust. OCUL is down 11% YTD but up 12% in 6 months. Analysts set price targets between $18 and $34. The company plans to submit an NDA for AXPAXLI in Q4 2026, with H.C. Wainwright raising its target to $25 and Citizens to $34.
2 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) shares rose after EyePoint Pharmaceuticals (EYPT) reported its DURAVYU trial missed its primary goal. Clear Street maintained a 'Buy' rating on OCUL, while B. Riley set a $37 target for FDMT. EYPT's stock fell 67% on the news, with OCUL and FDMT gaining 6% and 19% respectively.
2 min readBristol-Myers Squibb (BMY) reported Q2 revenues of $12.97B, up 5.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing estimates. Amphastar (AMPH) reported $183.9M in revenues, up 5.4% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market sentiment has shifted from AI to geopolitics.
3 min readModerna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.
3 min readOcular Therapeutix (OCUL) and 4D Molecular (FDMT) rose after EyePoint Pharmaceuticals (EYPT) said its DURAVYU late-stage wet AMD trial missed its main goal versus Eylea. Analysts cited potential competitive relief for OCUL’s Axpaxli and trial design benefits for FDMT’s 4D-150. OCUL gained 6%, FDMT 19%; EYPT shares fell 67%.
5 min readOcular Therapeutix (NASDAQ:OCUL) shares rose 6.32% to $10.81 after EyePoint (NASDAQ:EYPT) reported topline Phase 3 LUGANO results for Duravyu in wet AMD. EyePoint met key secondary endpoints but missed the primary visual acuity endpoint. Analysts said the data may still support filing prospects, while OCUL highlighted its Axpaxli (OTX-TKI) NDA planned for Q4 2026 with SOL-1 and interim SOL-R safety data.
4 min read
